Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hallucinogens | 13 | 2024 | 77 | 3.220 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 13 | 2024 | 72 | 2.400 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 2 | 2019 | 5 | 1.020 |
Why?
|
| Speech | 2 | 2020 | 85 | 0.630 |
Why?
|
| Psychotropic Drugs | 2 | 2020 | 79 | 0.630 |
Why?
|
| Internet | 3 | 2013 | 324 | 0.620 |
Why?
|
| Emotions | 3 | 2016 | 358 | 0.590 |
Why?
|
| Central Nervous System Stimulants | 3 | 2016 | 220 | 0.530 |
Why?
|
| Double-Blind Method | 12 | 2020 | 1727 | 0.530 |
Why?
|
| Salvia | 2 | 2010 | 2 | 0.450 |
Why?
|
| Affect | 3 | 2013 | 390 | 0.430 |
Why?
|
| Theobromine | 1 | 2013 | 3 | 0.430 |
Why?
|
| Methamphetamine | 6 | 2011 | 89 | 0.430 |
Why?
|
| Caffeine | 1 | 2013 | 84 | 0.390 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2010 | 4 | 0.370 |
Why?
|
| Hallucinations | 1 | 2010 | 29 | 0.360 |
Why?
|
| Vision, Ocular | 1 | 2010 | 71 | 0.350 |
Why?
|
| Vision Disorders | 1 | 2010 | 74 | 0.350 |
Why?
|
| Data Collection | 2 | 2013 | 377 | 0.340 |
Why?
|
| Self Report | 2 | 2010 | 300 | 0.340 |
Why?
|
| Plant Extracts | 2 | 2010 | 245 | 0.320 |
Why?
|
| Young Adult | 12 | 2020 | 6426 | 0.320 |
Why?
|
| Cannabinoid Receptor Modulators | 1 | 2008 | 3 | 0.320 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2008 | 15 | 0.320 |
Why?
|
| Endocannabinoids | 1 | 2008 | 31 | 0.300 |
Why?
|
| Cross-Over Studies | 5 | 2019 | 387 | 0.300 |
Why?
|
| Adult | 20 | 2020 | 26953 | 0.280 |
Why?
|
| Surveys and Questionnaires | 4 | 2010 | 2670 | 0.270 |
Why?
|
| Healthy Volunteers | 3 | 2016 | 147 | 0.270 |
Why?
|
| Substance-Related Disorders | 3 | 2013 | 422 | 0.250 |
Why?
|
| Benzofurans | 1 | 2024 | 9 | 0.240 |
Why?
|
| Male | 23 | 2024 | 42967 | 0.240 |
Why?
|
| Social Behavior | 3 | 2016 | 300 | 0.230 |
Why?
|
| Interpersonal Relations | 2 | 2016 | 178 | 0.230 |
Why?
|
| Heart Rate | 5 | 2014 | 496 | 0.230 |
Why?
|
| Empathy | 2 | 2016 | 150 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2013 | 1935 | 0.200 |
Why?
|
| Humans | 30 | 2024 | 90640 | 0.200 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2010 | 28 | 0.200 |
Why?
|
| Consensus | 1 | 2024 | 371 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2024 | 1242 | 0.200 |
Why?
|
| Female | 20 | 2020 | 46894 | 0.200 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2010 | 15 | 0.180 |
Why?
|
| Dextromethorphan | 1 | 2000 | 11 | 0.180 |
Why?
|
| Area Under Curve | 2 | 2019 | 338 | 0.170 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1999 | 4 | 0.170 |
Why?
|
| Naloxone | 2 | 1999 | 68 | 0.170 |
Why?
|
| Buprenorphine | 2 | 1999 | 41 | 0.160 |
Why?
|
| Narcotic Antagonists | 2 | 1999 | 162 | 0.150 |
Why?
|
| Cognition | 2 | 2015 | 588 | 0.150 |
Why?
|
| Language | 1 | 2020 | 157 | 0.150 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 513 | 0.150 |
Why?
|
| Opioid-Related Disorders | 2 | 1999 | 194 | 0.140 |
Why?
|
| Adolescent | 4 | 2013 | 9354 | 0.120 |
Why?
|
| Blood Pressure | 4 | 2014 | 906 | 0.120 |
Why?
|
| Administration, Oral | 3 | 2013 | 671 | 0.120 |
Why?
|
| Disclosure | 1 | 2016 | 109 | 0.120 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 89 | 0.110 |
Why?
|
| Anesthetics, Dissociative | 1 | 2013 | 5 | 0.110 |
Why?
|
| Administration, Inhalation | 2 | 2010 | 191 | 0.110 |
Why?
|
| Ketamine | 1 | 2013 | 25 | 0.100 |
Why?
|
| Urologic Diseases | 1 | 2013 | 44 | 0.100 |
Why?
|
| Substance Abuse Detection | 1 | 2011 | 12 | 0.090 |
Why?
|
| Diterpenes, Clerodane | 1 | 2010 | 1 | 0.090 |
Why?
|
| Urinalysis | 1 | 2011 | 31 | 0.090 |
Why?
|
| Amines | 1 | 2010 | 28 | 0.090 |
Why?
|
| Nootropic Agents | 1 | 2010 | 10 | 0.090 |
Why?
|
| Ethics, Clinical | 1 | 2010 | 48 | 0.090 |
Why?
|
| Weight Gain | 1 | 2011 | 121 | 0.090 |
Why?
|
| Placebos | 1 | 2010 | 211 | 0.090 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2010 | 24 | 0.090 |
Why?
|
| Central Nervous System Depressants | 1 | 2010 | 45 | 0.090 |
Why?
|
| Antipsychotic Agents | 1 | 2011 | 139 | 0.080 |
Why?
|
| Impulsive Behavior | 1 | 2013 | 290 | 0.080 |
Why?
|
| Brain Chemistry | 2 | 2008 | 122 | 0.080 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 108 | 0.080 |
Why?
|
| Attention | 1 | 2013 | 399 | 0.080 |
Why?
|
| Nasal Decongestants | 1 | 2008 | 10 | 0.080 |
Why?
|
| Bicycling | 1 | 2008 | 14 | 0.080 |
Why?
|
| Nonprescription Drugs | 1 | 2008 | 16 | 0.080 |
Why?
|
| Nerve Fibers | 1 | 2008 | 48 | 0.080 |
Why?
|
| Athletic Performance | 1 | 2008 | 31 | 0.080 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 135 | 0.080 |
Why?
|
| Glutamic Acid | 1 | 2008 | 154 | 0.070 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 108 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2008 | 132 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2008 | 365 | 0.070 |
Why?
|
| Rats | 3 | 2024 | 4061 | 0.070 |
Why?
|
| Visual Perception | 1 | 2010 | 327 | 0.070 |
Why?
|
| Middle Aged | 6 | 2010 | 26347 | 0.070 |
Why?
|
| Cerebellum | 1 | 2008 | 250 | 0.070 |
Why?
|
| Animals | 5 | 2024 | 27715 | 0.060 |
Why?
|
| Synaptosomes | 1 | 2024 | 10 | 0.060 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2024 | 6 | 0.060 |
Why?
|
| Biogenic Monoamines | 1 | 2024 | 9 | 0.060 |
Why?
|
| Serotonin | 2 | 2024 | 221 | 0.060 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2024 | 37 | 0.060 |
Why?
|
| Dopamine | 2 | 2024 | 277 | 0.060 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2024 | 48 | 0.060 |
Why?
|
| Norepinephrine | 1 | 2024 | 172 | 0.060 |
Why?
|
| Research Design | 2 | 2013 | 590 | 0.060 |
Why?
|
| Aged | 2 | 2010 | 19424 | 0.050 |
Why?
|
| Health Policy | 1 | 2024 | 191 | 0.050 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2002 | 36 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2010 | 4348 | 0.050 |
Why?
|
| Informed Consent | 1 | 2024 | 277 | 0.050 |
Why?
|
| Papio | 1 | 2001 | 82 | 0.050 |
Why?
|
| Time Factors | 4 | 2010 | 5366 | 0.040 |
Why?
|
| Psycholinguistics | 1 | 2020 | 10 | 0.040 |
Why?
|
| Semantics | 1 | 2020 | 48 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2020 | 139 | 0.040 |
Why?
|
| Species Specificity | 1 | 2001 | 690 | 0.040 |
Why?
|
| Oxytocin | 1 | 2020 | 73 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2001 | 203 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 1999 | 795 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2008 | 3431 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2782 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2000 | 739 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2001 | 1142 | 0.030 |
Why?
|
| Biomarkers | 2 | 2011 | 1800 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2001 | 2338 | 0.030 |
Why?
|
| Dysuria | 1 | 2013 | 8 | 0.030 |
Why?
|
| Hematuria | 1 | 2013 | 50 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2013 | 157 | 0.030 |
Why?
|
| Reaction Time | 1 | 1993 | 312 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2013 | 162 | 0.020 |
Why?
|
| Appetite | 1 | 2011 | 26 | 0.020 |
Why?
|
| Risk Factors | 1 | 2002 | 5583 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 303 | 0.020 |
Why?
|
| Administration, Sublingual | 1 | 2010 | 5 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 19 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 111 | 0.020 |
Why?
|
| Deuterium | 1 | 2010 | 33 | 0.020 |
Why?
|
| Biological Availability | 1 | 2010 | 91 | 0.020 |
Why?
|
| Half-Life | 1 | 2010 | 97 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2010 | 52 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1993 | 498 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 595 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 238 | 0.020 |
Why?
|
| Body Temperature | 1 | 2010 | 126 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2002 | 898 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 220 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2010 | 138 | 0.020 |
Why?
|
| Terpenes | 1 | 2008 | 18 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 204 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2010 | 328 | 0.020 |
Why?
|
| United States | 1 | 2000 | 7142 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 437 | 0.020 |
Why?
|
| Mice | 1 | 2001 | 11949 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 850 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1871 | 0.020 |
Why?
|
| Oxygen | 1 | 2010 | 747 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 3813 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 2002 | 48 | 0.010 |
Why?
|
| Prolactin | 1 | 2002 | 89 | 0.010 |
Why?
|
| Hormones | 1 | 2002 | 139 | 0.010 |
Why?
|
| Psychometrics | 1 | 2002 | 332 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2002 | 302 | 0.010 |
Why?
|
| Cardiac Output | 1 | 2000 | 154 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 244 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2000 | 188 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1999 | 47 | 0.010 |
Why?
|
| Narcotics | 1 | 1999 | 71 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2000 | 482 | 0.010 |
Why?
|
| Morphine | 1 | 1999 | 130 | 0.010 |
Why?
|